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Adrenocorticotropic hormone (ACTH) has a renoprotective
effect in chronic kidney disease; however, its effect on acute
kidney injury (AKI) remains unknown. In a rat model of tumor
necrosis factor (TNF)–induced AKI, we found that ACTH gel
prevented kidney injury, corrected acute renal dysfunction,
and improved survival. Morphologically, ACTH gel
ameliorated TNF-induced acute tubular necrosis, associated
with a reduction in tubular apoptosis. While the
steroidogenic response to ACTH gel plateaued, the kidney-
protective effect continued to increase at even higher doses,
suggesting steroid-independent mechanisms. Of note, ACTH
also acts as a key agonist of the melanocortin system, with its
cognate melanocortin 1 receptor (MC1R) abundantly
expressed in renal tubules. In TNF-injured tubular epithelial
cells in vitro, ACTH reinstated cellular viability and eliminated
apoptosis. This beneficial effect was blunted in MC1R-
silenced cells, suggesting that this receptor mediates the
anti-apoptotic signaling of ACTH. Moreover, ACTH gel
protected mice against cecal ligation puncture–induced
septic AKI better than a-melanocyte-stimulating hormone: a
protein equal in biological activity to ACTH except for
steroidogenesis. Thus, ACTH has additive renoprotective
actions achieved by both steroid-dependent mechanisms
and MC1R-directed anti-apoptosis. ACTH may represent a
novel therapeutic strategy to prevent or treat AKI.
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published online 16 January 2013
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Acute kidney injury (AKI) is a complex and heterogeneous
disease entity characterized by an abrupt loss of kidney
function that could be ascribed to numerous causes. In the
past 30 years, although progress is indeed being made in
identifying biomarkers for early diagnosis of AKI,1–3
management of AKI is still largely limited to general
supportive measures;4,5 no specific intervention that either
prevents or treats the injured kidney or improves survival has
been successfully developed.6 It is imperative to develop a
novel, effective, and pragmatic approach to prevent kidney
injury or to promote kidney repair and regeneration.7
Adrenocorticotropic hormone (ACTH) is an important
component of the hypothalamic–pituitary–adrenal axis.8,9 In
the 1950s and the early 1960s, ACTH was widely used for
the treatment of lipoid nephrosis.9–11 Recent clinical and
experimental evidence suggests that ACTH has a
renoprotective effect in chronic kidney diseases.9,11,12 Besides
governing steroidogenesis, ACTH is also an important
physiological agonist of the melanocortin system.9,13 This
system comprises multiple components, including five class A
guanine nucleotide–binding protein (G protein)–coupled
melanocortin receptors (MCRs) MC1RBMC5R; endogenous
antagonists; and peptide agonists derived from the anterior
pituitary gland, including a-melanocyte-stimulating hormone
(MSH), b-MSH, g-MSH, and ACTH.9,13 Accumulating data
demonstrate that melanocortins,14 in particular a-MSH15 and
its synthetic mimetics,16 possess a potent protective activity in
acute injuries in multiple organ systems,17–19 including the
kidney.15 Nevertheless, although a-MSH has similar MCR
agonizing potency as its parent molecule ACTH,9,13 the effect
of ACTH on AKI has been barely investigated. This study
examined the effect of ACTH gel (HP Acthar Gel, Questcor
Pharmaceuticals, Hayward, CA), which is an FDA-approved
formulation of natural porcine ACTH, on a rat model of AKI
induced by tumor necrosis factor (TNF)20–22 and a murine
model of septic AKI induced by cecal ligation puncture
(CLP).16,23,24 We found that ACTH has a kidney-protective
effect on AKI that is mediated by both steroid-dependent and
-independent mechanisms.
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RESULTS
ACTH gel improves survival of rats with TNF-induced
systemic organ injury
TNF is a pleiotropic prodeath and proinflammatory cytokine
involved in the pathogenesis of multiple organ dysfunction
and systemic inflammatory response syndrome.20,21 A single
injection of exogenous recombinant TNF immediately
disturbed systemic homeostasis and resulted in 40%
mortality within 8 h (Figure 1a). ACTH pretreatment
reduced mortality and markedly improved general survival
in a dose-dependent manner: even at low doses (2 IU/kg),
pretreatment with ACTH increased survival to 80%; at higher
doses, ACTH treatment resulted in 100% survival from TNF
stimulation (Figure 1a), suggesting a general beneficial effect
of ACTH. To determine whether ACTH gel therapy has a
systemic beneficial action, mean arterial pressure (MAP) was
measured and the injury of the liver and lung was assessed.
TNF injection induced a profound drop in MAP and caused
a hypotensive shock (Figure 1b). Furthermore, TNF elicited
acute liver injury as evidenced by the elevated serum levels of
hepatic enzymes including aspartate aminotransferase and
alanine aminotransferase. TNF also augmented wet to dry
lung weight ratios, in agreement with the formation of acute
pulmonary edema. ACTH gel treatment (10 IU/kg) signifi-
cantly corrected the blood pressure, lowered serum aspartate
aminotransferase and alanine aminotransferase levels
(Figure 1c), and normalized wet to dry lung weight ratios
(Figure 1d), signifying a general improvement in hemody-
namics and systemic organ injury.
ACTH attenuates kidney injury and dysfunction in TNF-
injured rats
To examine the effect of ACTH on TNF-induced kidney
injury and to determine the minimal dose of ACTH gel that
Survival
Su
rv
iva
l p
ro
ba
bi
lity
 (%
)
100
95
90
85
80
75
70
65
60
55
50
Number at risk
W
et
/d
ry
 lu
ng
 w
ei
gh
t r
at
io
12
8
4
0
AST
ALT
*
*
*
*
350
300
250
200
150
100
50
0
Sa
line
Se
ru
m
 A
ST
/A
LT
 le
ve
ls
(IU
/L)
M
AP
 (m
m 
Hg
)
120
80
40
0
Sa
line
AC
TH TN
F
AC
TH
+T
NF
AC
TH TN
F
AC
TH
+T
NF
Sa
line
AC
TH TN
F
AC
TH
+T
NF
Vehicle 10 10
10
10
10
P =0.004, by log-rank test
10 8
8 8
6 6
10ACTH(2IU/kg)+TNF
ACTH(5IU/kg)+TNF
ACTH(10IU/kg)+TNF
ACTH(20IU/kg)+TNF
ACTH(2IU/kg)+TNF
ACTH(5IU/kg)+TNF
ACTH(10IU/kg)+TNF
ACTH(20IU/kg)+TNF
10
10
10
TNF
Vehicle
TNF
Time (h)
Groups
0 2 3 4 5 6 7 81
Figure 1 | Adrenocorticotropic hormone (ACTH) gel treatment significantly improves survival and ameliorates systemic organ injury in
tumor necrosis factor (TNF)–injured rats. (a) Rats were pretreated subcutaneously with saline or ACTH gel at indicated doses 60min before
intravenous bolus injection of recombinant rat TNF (2mg/kg wt). Rats were evaluated hourly and survival was recorded. Survival rate was
plotted against the time course. The survival probability of rats receiving different treatment was determined by Kaplan–Meier survival analysis.
P¼ 0.0040 among the groups by log-rank test. (b–d) Rats were pretreated subcutaneously with saline or ACTH gel (10 IU/kg) 60min before
intravenous bolus injection of recombinant rat TNF (2mg/kg wt). (b) Mean arterial pressure (MAP) was measured and rats were killed 8 h later.
(c) Blood was collected and serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured to assess
acute liver injury. (d) Lung was excised and wet to dry lung weight ratio was determined to assess acute lung injury. *Po0.05 versus TNF-alone-
treated group (n¼ 5).
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can maximally protect the kidney, fluorescence-labeled
viable rat alveolar macrophages (RAM) were infused into
the carotid artery of some animals 60min before they were
killed.22 Tissues were processed for fluorescent microscopic
analysis. As shown in Figure 2a, many fluorescent RAM cells
were sequestered in kidneys of TNF-injured animals, most
prominently in the interstitium of the juxtamedullary
cortex. Very few were found in kidneys from rats treated
with saline or ACTH gel alone. ACTH gel treatment
remarkably prevented the sequestration of RAM in the
kidney, denoting a kidney-protective and anti-inflammatory
effect. The amount of RAM infiltration was quantified by
fluorometric analysis of homogenized kidney tissues, which
revealed a dose-dependent inhibitory effect of ACTH gel on
fluorescent RAM sequestration in TNF-injured kidney,
consistent with the morphologic observations (Figure 2b).
Because no further reduction in macrophage sequestration
in the kidney was noted in animals treated with ACTH gel at
doses higher than 10 IU/kg, the dose of 10 IU/kg was thus
adopted as the optimal dose of ACTH gel for treatment of
kidney injury in the following studies. At this dose, ACTH
gel treatment also remarkably prevented the TNF-induced
sequestration of RAM in the liver and lung shown by
fluorometric analysis of liver and lung homogenates
(Supplementary Figure 1a online). This was further
corroborated by direct fluorescent microscopy of lung and
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Figure 2 | Adrenocorticotropic hormone (ACTH) gel prevents acute renal injury in a dose-dependent manner and prominently
improves kidney dysfunction at an optimal dose. Rats were treated with ACTH gel and tumor necrosis factor (TNF) as described in Figure 1
and were killed at the indicated time. To estimate an optimal kidney-protective dose of ACTH gel, fluorescence-labeled rat alveolar macrophage
(RAM) cells were infused into the carotid artery 60min before killing. Kidney sections were counterstained with Evans blue (red) to visualize and
evaluate RAM sequestration (green; a), which was further quantified by (b) fluorometric analysis of kidney homogenates; *Po0.05 versus TNF-
alone-treated group (n¼ 5); bar¼ 100mm in a. (c) At 10 IU/kg, ACTH gel significantly attenuates TNF-impaired glomerular filtration rate (GFR) as
estimated by inulin clearance; *Po0.05 versus other groups (n¼ 5). (d) Albumin levels in the collected ureteral urine were measured by
enzyme-linked immunosorbent assay and demonstrated that ACTH gel at 10 IU/kg markedly abrogates TNF-induced microalbuminuria.
*Po0.05 versus other groups (n¼ 5). BW, body weight.
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liver specimens (Supplementary Figure 1b online), consis-
tent with a systemic protective effect of ACTH. To further
validate the renoprotective action of ACTH gel, kidney
function was estimated by the glomerular filtration rates
measured by inulin clearance assay and demonstrated that
ACTH gel significantly improved acute kidney dysfunction
(Figure 2c). Moreover, ACTH gel treatment also promi-
nently diminished microalbuminuria induced by TNF
(Figure 2d).
ACTH gel ameliorates histological AKI induced by TNF
Morphologically, TNF induced a typical pattern of acute
tubular necrosis, characterized by epithelial simplification,
vacuolization of proximal tubular epithelium, luminal
ectasia, epithelial necrosis, sloughing of tubular cell into
lumen, loss of brush border, nuclear enlargement and
pleomorphism, nuclear pyknosis and karyolysis, and
prominent inflammatory infiltration, concomitant with
tubular apoptosis (Figure 3a). ACTH gel at a dose of
10 IU/kg remarkably ameliorated these histological lesions
evoked by TNF (Figure 3a). Semiquantitative morphometric
analysis confirmed and quantified the morphologic findings
and revealed that ACTH gel treatment significantly reduced
the tubulointerstitial injury score and the dilation sloughing
score (Figure 3b and d). Computerized morphometric
analysis demonstrated that the area of vacuolization, as well
as the number of necroapoptotic nuclei in TNF-injured
kidneys, was remarkably diminished after ACTH gel
treatment (Figure 3c and e). TNF is one of the prototypes
of prodeath cytokines that could promote cell apoptosis.21
In support of this, TNF injection elicited massive cellular
apoptosis in the kidney, as indicated by TdT-mediated
dUTP nick-end labeling (TUNEL) staining, mainly located
to the renal tubules in the juxtamedullary cortex
(Figure 4a). ACTH gel treatment drastically abrogated the
proapoptotic effect of TNF and greatly diminished the
TUNEL positivity in the kidney (Figure 4a). Absolute
counting of TUNEL-positive cell number corroborated the
morphologic findings (Figure 4c). To examine whether the
change in tubular cell apoptosis is associated with the
change in the activity of proapoptotic signaling pathway,
kidney specimens were stained for cleaved or active form of
caspase-3, a pivotal transducer of the apoptotic-signaling
pathway. Shown in Figure 4a, prominent expression of
cleaved caspase-3 was induced predominantly in tubules in
the juxtamedullary cortex of TNF-injured kidneys, and this
could be markedly blunted by ACTH gel treatment.
Moreover, immunoblot analysis of kidney homogenates
indicated that ACTH gel treatment markedly attenuated the
TNF-induced reduction in the ratios of intact/cleaved
caspase-3 and phosphorylated glycogen synthase kinase
(GSK)3b/GSK3b (Figure 4b and d), denoting that ACTH
abrogated caspase-3-directed cell death and blunted GSK3b
activation, which has been shown to be proapoptotic25 and
has a detrimental role in AKI.26
Steroid-independent mechanism contributes to kidney
protection by ACTH
ACTH possesses a canonical steroidogenic activity, through
which ACTH directs the adrenal release of glucocorticoid, a
typical immunomodulatory and anti-inflammatory hormone
that could attenuate renal inflammation and thus might
mediate the renoprotective effects of ACTH.9,13 Indeed, in
TNF-injured animals, the tubulointerstitial injury score
(Figure 5b) inversely correlated with steroidogenic response
to ACTH gel as determined by the plasma levels of
corticosterone (Figure 5a) at low doses. However, although
the steroidogenic response to ACTH gel above a dose of 5 IU/
kg reached a plateau, the renoprotective effect continued to
increase with even higher doses (10 IU/kg, 20 IU/kg), suggest-
ing that steroid-independent mechanisms also contribute.
Melanocortin 1 receptor is the major intrarenal MCR that is
predominantly expressed on renal tubular cells
To explore the steroid-independent kidney-protective me-
chanisms, the expression of all MCRs was profiled in rat
kidneys by reverse transcriptase–PCR (RT-PCR). The MCRs
are the product of small, intronless genes; hence, genomic
contamination complicates mRNA-based expression ana-
lyses, including RT-PCR.9,27 To avoid this issue, samples of
mRNA extracted from kidney tissues were subjected to
DNase treatment before further processes. Shown in
Figure 6a, rat kidney tissues evidently expressed melanocortin
1 receptor (MC1R) mRNA and to a much lesser extent
MC5R mRNA. A parallel PCR amplification of an intron of
the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
gene was carried out simultaneously using the same cDNA
samples (Table 1) to confirm the quality of mRNA: no band
of the GAPDH intron was detected (Figure 6a), indicating no
genomic contamination of the mRNA samples. To validate
the RT-PCR results, immunoblot analysis of kidney homo-
genates was performed and showed that both MC1R and
MC5R were expressed in the kidney; however, only MC1R is
expressed in both rat kidney and cultured proximal tubular
epithelial (IRPTC) cells (Figure 6b). To localize the MCR
expression in the kidney, fluorescent immunohistochemistry
staining was conducted and showed that MC1R was expressed
intensely and predominantly by renal tubules and very weakly
by glomeruli, whereas MC5R was weakly and sporadically
expressed by the interstitial cells (Figure 6c). TNF injury
enhanced the intensity of MC1R expression in the tubules,
but had minor effect on MC5R expression (Figure 6c). In
cultured IRPTC cells, fluorescent immunocytochemistry
staining consistently revealed punctate staining of MC1R
(Figure 6d), in agreement with a typical staining pattern of
cytoplasmic membrane receptors. No fluorescent staining was
seen when preimmune IgG was used as primary antibodies for
either immunohistochemistry or immunocytochemistry stain-
ing (Figure 6c and d). Moreover, in cells transfected with
MC1R-specific siRNA, the immunofluorescent staining signal
was drastically diminished (Figure 6d), denoting a high speci-
ficity of the MC1R immunostaining. Collectively, the above
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Figure 3 | Adrenocorticotropic hormone (ACTH) gel therapy ameliorates histological acute kidney injury in tumor necrosis factor
(TNF)–injured rats. Rats were pretreated subcutaneously with saline or ACTH gel (10 IU/kg) 60min before intravenous bolus injection of
recombinant rat TNF (2mg/kg wt). (a) Rats were killed 8 h later and kidney sections were prepared for hematoxylin and eosin (H&E) staining
to evaluate histological injury; original magnification, 200 (high-power view, x400); necroapoptotic nuclei highlighted by arrowheads.
G, glomerulus. Semiquantitative ((b) tubulointerstitial injury score and (d) tubular dilation/sloughing score), as well as computerized ((c)
vacuolization area and (e) necroapoptotic nuclei), morphometric analysis was used to estimate kidney injury. *Po0.05 versus other groups
(n¼ 5).
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findings suggest that MC1R is the major MCR for ACTH in
the kidney that is located to renal tubular cells.
MC1R mediates the anti-apoptotic action of ACTH on renal
tubular cells
In IRPTCs stimulated with TNF in a culture model in which
the steroidogenic circuit is absent, ACTH treatment markedly
reinstated cellular viability in a dose-dependent manner with
a maximal effect observed above 10 8M (Figure 7a), again
suggesting that ACTH has a direct kidney-protective activity
that is independent of steroidogenesis. To examine whether
this steroid-independent anti-apoptotic/prosurvival effect of
ACTH is mediated via its cognate MC1R on tubular epithelial
cells, RNA interference (RNAi) was applied to specifically
silence the MC1R expression in cultured IRPTC cells. Shown
in Figure 7b, RNAi with MC1R-specific siRNA (si-MC1R)
drastically knocked down MC1R expression. By contrast,
RNAi with scramble siRNA (si-Control) barely affected its
expression, as validated by immunoblot analysis (Figure 7b)
and immunocytochemistry staining (Figure 7d). TNF
stimulation impaired cellular viability, as estimated by
tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetra-
zolium bromide) assay (Figure 7c), and induced apoptosis, as
determined by PARP activation (Figure 7b) and TUNEL
staining (Figure 7d and e). In cells transfected with scrambled
siRNA, ACTH significantly counteracts TNF-induced apop-
totic responses (Figure 7b–e). The beneficial effects of ACTH
were largely abolished in MC1R-silenced cells, suggesting that
MC1R is indispensable for ACTH’s anti-apoptotic action in
renal tubular cells.
ACTH gel protects from septic AKI via an additive action
To explore whether ACTH has a kidney-protective
efficacy comparable to a-MSH and to ascertain whether the
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Figure 4 | Adrenocorticotropic hormone (ACTH) gel prevents renal tubular cell apoptosis in tumor necrosis factor (TNF)–injured rats.
Rats were pretreated subcutaneously with saline or ACTH gel (10 IU/kg) 60min before intravenous bolus injection of recombinant rat TNF
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kidney-protective activity of ACTH is also applicable to other
forms of AKI, the effect of ACTH gel was compared with that
of a-MSH and reexamined in a murine model of septic AKI
induced by CLP. Mice were treated with ACTH gel (10 IU/kg)
or an equal molar amount of a-MSH (71 mg/kg), subjected to
CLP and followed up for 24 h. CLP-induced polymicrobial
sepsis disturbed systemic hemodynamics, caused hypotensive
shock, and resulted in a histology of acute tubular injury, as
well as kidney dysfunction, reflected by an increase in the
serum creatinine level. Consistent with previous reports,16
a-MSH treatment markedly ameliorated histological AKI
(Figure 8a and c) and kidney dysfunction (Figure 8b) and
corrected hypotension (Figure 8d) in septic mice. Compared
with a-MSH, which is equal in biological activity to ACTH,
except for steroidogenesis, ACTH gel exerted a much more
potent protective effect, evidenced by significantly better
kidney histology and more improvements in tubular injury
scores, serum creatinine levels, and blood pressure (Figure 8).
These data suggest that the kidney-protective effect exerted
by ACTH might be ascribed to an additive beneficial action
achieved by both steroid-dependent mechanisms and MC1R-
mediated a-MSH-like activities.
DISCUSSION
AKI remains a therapeutic challenge despite advances in
supportive care. In the present study, supplementation of
exogenous ACTH attenuated acute renal histological injury,
improved kidney dysfunction, and promoted general survival
in animal models of AKI. To the best of our knowledge, this
study is the first to demonstrate a kidney-protective action of
ACTH on AKI.
ACTH carries vital biologic information from the brain to
the adrenal cortex and to other parts of the mammalian
body.8,9 As a crucial component of the hypothalamic
–pituitary–adrenal axis, ACTH stimulates the adrenal pro-
duction of corticosteroids.8,9 The efficacy of corticosteroids
on AKI remains highly controversial;28,29 however, its potent
anti-inflammatory activity has been widely acknowledged.30
Thus, the beneficial effect of ACTH on AKI observed in this
study might be explained partially by the steroidogenic action
through which ACTH upregulates corticosterone production
and subsequently suppresses TNF-induced acute inflam-
matory injury in the kidney. In support of this, severity of the
TNF-induced tubulointerstitial injury inversely correlated
with steroidogenic response to ACTH, as determined by the
plasma levels of corticosterone at low doses. However, the
steroidogenic response to ACTH above a dose of 5 IU/kg
reached a plateau and the renoprotective effect continued to
increase with even higher doses, suggesting that steroid-
independent mechanisms also contribute.
Besides governing steroidogenesis, ACTH is also an
important physiological agonist of the melanocortin system,
which has an integral role in the homeostatic control of a
diverse array of physiological functions, including cellular
survival, proliferation, anti-inflammation, and immunomo-
dulation.9,13 The anti-apoptotic and kidney-protective action
on AKI by a-MSH, another agonist of the melanocortin
system, has been extensively examined and reproducibly
demonstrated in multiple animal models of AKI, including
ischemia–reperfusion injury,31–33 renal toxicity,34,35 and
ureteral obstruction.36 a-MSH shares the same amino-acid
sequence as the N-terminus of ACTH, and possesses all of
ACTH’s biological activities with similar potency, except
steroidogenesis.9,13 Therefore, the steroid-independent
mechanisms accounting for the kidney-protective effect of
ACTH might be attributable to a non-steroidogenic
melanocortin activity or an a-MSH-like activity. Thus,
ACTH might have an additive action attributable to both
corticosteroid–mediated mechanisms and the non-steroido-
genic a-MSH-like activities. Accordingly, owing to its unique
steroidogenic effect, ACTH might be superior to a-MSH in
protecting kidney from acute injuries, as revealed in our
study of CLP-induced sepetic AKI.
The detailed molecular mechanism underlying the anti-
apoptotic and kidney-protective effect of ACTH and a-MSH
remains elusive, and whether ACTH and a-MSH directly
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attenuates acute kidney injury in tumor necrosis factor
(TNF)–injured rats via, at least in part, a steroid-independent
mechanism. Rats were pretreated with saline or ACTH gel
subcutaneously at indicated doses 60min before intravenous bolus
injection of recombinant rat TNF (2mg/kg wt). Rats were killed 8 h
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immunosorbent assay and suggested that the steroidogenic
response to ACTH above a dose of 5 IU/kg reaches a plateau;
*Po0.05 versus other groups (n¼ 5); &not significant. (b) Severity of
tubulointerstitial injury was scored as stated in Figure 3 and revealed
that the renoprotective effect of ACTH continues to increase with
even higher doses than 5 IU/kg, suggesting that steroid-independent
mechanisms also contribute to kidney protection; *Po0.05 versus
other groups (n¼ 5); #Po0.05.
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targets kidney parenchymal cells has been barely investigated.
Our study found for the first time that MC1R, a cognate
receptor with high affinity for both a-MSH and ACTH, is the
major MCR that is abundantly expressed in the kidney and
predominantly distributed on tubules, denoting renal tubules
as a direct therapeutic target for both ACTH and a-MSH.
Indeed, ACTH treatment of tubular epithelial cells in a
culture model in which the steroidogenic circuit is absent
drastically obliterated TNF-induced apoptosis and reinstated
cellular viability. Furthermore, MC1R silencing largely
abrogated ACTH’s beneficial effect, suggesting that MC1R
mediates this cytoprotective effect. In agreement with our
observations, Masser et al.37 demonstrated the dramatic
worsening of experimental intestinal injury in mice with a
nonfunctional MC1R. Moreover, the anti-apoptotic/prosur-
vival effect of MC1R signaling has been demonstrated
previously in human melanocytes.38,39 Treatment with
a-MSH results in the reduction of ultraviolet radiation–
elicited apoptosis, and this effect was independent of
melanin synthesis, in agreement with an MC1R-mediated
non-pigmentary anti-apoptotic mechanism.38,39 Consistently,
our data suggest that ACTH intercepts the caspase-directed
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subjected to immunoblot analysis for MC1R and MC5R. Samples prepared from skin and testis served as positive controls. Rat kidney expresses
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proapoptotic signaling pathway and obliterates GSK3b
activation, which promotes apoptosis and plays dirty in
AKI.26
Systemic inflammatory response, as well as immune
dysfunction, also plays an important role in the pathogenesis
of AKI.40,41 Evidence suggests that melanocortins such as a-
MSH and ACTH display a potent systemic protective activity
directly via MCRs expressed on most immune and non-
immune cells.27 Therefore, in addition to a direct kidney
effect, ACTH might prevent AKI via systemic protection,
immunomodulation, and anti-inflammation. Indeed, our
data indicate that ACTH gel treatment has a systemic
beneficial action that corrected hypotension and improved
histological injuries and inflammation in multiple organs
including the liver and lung.
In summary, ACTH gel, an FDA-approved formulation of
natural ACTH for the treatment of nephrotic syndrome, can
also ameliorate acute renal histological injury, correct acute
kidney dysfunction, and improve general survival in animal
models of AKI. ACTH ameliorates AKI by an additive action
exerted possibly via both steroid-dependent mechanisms
and MC1R-directed anti-apoptotic signaling. Our findings
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Table 1 |Nucleotide sequences of the primers used for PCR
Molecule Forward primer (50-30) Reverse primer (50-30) Amplimer size (bp)
MC1R TGTGGTAGCCATCACCAAAA CCAGGAAGCAGAGACTGGAC 230
MC2R ATCTGCAGTTTGGCCATTTC GCAATCACAGACAGGCTGAA 188
MC3R AGGACCAATTCATCCAGCAC AGGGCTTTCCTAACCGTCAT 160
MC4R CTTTTACGCGCTCCAGTACC GTAATTGCGCCCTTCATGTT 285
MC5R CCTCGGAGGACAACATCCTA CTAGGCTGCCCACAAAGAAG 189
GAPDH exon GGTGATGCTGGTGCTGAGTA ACTGTGGTCATGAGCCCTTC 272
GAPDH intron AGCTGTTGCTCCCCTTGTAA ATCCATCACCTGGCCTACAG 417
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suggest that ACTH may represent a novel and pragmatic
kidney-protective strategy to prevent or treat AKI.
MATERIALS AND METHODS
Cell culture
IRPTC cells, provided by Dr Julie Ingelfinger, were grown in Dulbecco’s
modified Eagle’s medium/F12 that contained 5% fetal bovine serum.
Recombinant rat TNF (R&D Systems, Minneapolis, MN) and porcine
ACTH (Sigma, St Louis, MO) were used to treat the culture at indicated
concentrations. RAM cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA) and were cultured in Ham’s F12K
containing 15% fetal bovine serum. For fluorescent viable labeling, RAM
cells (1107) were incubated in medium containing 5mg/ml Calcein-
AM (Molecular Probes, Eugene, OR) at 37 1C for 30min.
Cellular viability assay
A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
assay was used to assess cell viability as described previously.
Fluorescent immunocytochemistry
Cells were fixed with 4% paraformaldehyde. After serum
blocking for 30min, cells were incubated with the primary
antibody to indicated MCR (Alomone Labs, Jerusalem, Israel) or
preimmune IgG and then with the Alexa fluorophore 488–conjugated
secondary antibody (Invitrogen, Carlsbad, CA). Finally, cells were
counterstained with 40,6-diamidino-2-phenylindole and mounted
with Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA) and visualized using a fluorescence microscope.22
RNA interference
Predesigned siRNA duplex was chemically synthesized by Ambion
(Austin, TX). MC1R-specific siRNA sequence (50-GAGGUUGAA-
GUUCUUGAAGtt-30) was designed according to the complete
coding sequence of rat MC1R gene (GenBank accession no.
AB576619.2). In addition, a scrambled siRNA sequence (50-
GCGAGUAGCGCUAGGAAGUtt-30) without sequence similarity
to any known gene sequences from mouse, rat, or human was
designed as control for RNAi.42 Efficiency of lipofectamine
(Invitrogen)-mediated gene-silencing efficiency was assessed by
immunocytochemistry staining or immunoblot analysis for MC1R.
Near-complete (B80%) suppression of MC1R protein expression
was observed in cells transfected with MC1R-specific siRNA.
RNA extraction and RT-PCR
Genomic DNA (gDNA) and mRNA were extracted from kidney
cortex tissues or cultured cells, and the first-strand cDNA was
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prepared after mRNA was treated with DNase to eliminate potential
gDNA contamination. PCR amplification of the intron or exon of
GAPDH, as well as indicated MCRs, was carried out as previously
described using primers listed in Table 1. To confirm no contami-
nation of mRNA by gDNA, cDNA samples were subjected to PCR
amplification of an intron and an exon of GAPDH gene; a sample of
gDNA served as the positive control. PCR products resolved in
agarose gels were photographed under ultraviolet light.
Animal experimental design
Animal experimental studies were approved by the institution’s
Animal Care and Use Committee, and they conform to the USDA
regulation and NIH guidelines for human care and use of laboratory
animals.
Rat model of TNF induced AKI
Male Sprague–Dawley rats with initial weights of 200–250 g were
pretreated subcutaneously with saline or ACTH gel at indicated
doses 60min before injection of recombinant rat TNF (2mg/kg wt)
(R&D system) via tail vein. Rats were evaluated hourly and survival
was recorded. To determine an optimal dose of ACTH gel for kidney
protection, RAM infusion assay was performed in some rats as
reported before.22 In brief, rats were anesthetized, at indicated time
points after TNF injection, placed on a heated table to keep constant
body temperature, and maintained at an euvolemic state. Fluore-
scent-labeled RAM cells (1104) resuspended in normal saline (NS)
were infused via the carotid artery. After a 15-min equilibration
period, MAP was measured and glomerular filtration rate was
determined by inulin clearance assay as described before.22 Rats were
killed 60min after RAM cell infusion, and ureteral urine and blood
were collected. Organs were collected for further investigation. To
quantify the fluorescent RAM cells sequestrated in the organs, tissue
homogenates with an equal amount of protein (100mg) were
subjected to fluorometric analysis.
Mouse model of septic AKI induced by CLP
Male CD-1 mice at the age of 8 weeks were subjected to CLP surgery
to induce sepsis as previously described.16,23,24 In brief, under
isoflurane anesthesia, 1.5 cm of the cecal tip was ligated using a 4-0
silk suture and punctured twice with a 21-gauge needle. An
approximately 1-mm column of fecal material was expressed. In
sham-operated mice, the cecum was isolated but neither ligated nor
punctured. After surgery, all mice received 1ml of prewarmed NS
intraperitoneally. Treatment with fluid and antibiotic was started at
12 h after surgery with subcutaneous injection of imipenem/
cilastatin (14mg/kg) in 1ml of NS. Acthar gel (10 IU/kg) or equal
molar amounts of a-MSH (71mg/kg, Sigma; prepared in saline
containing 16% gelatin) was administered subcutaneously 60min
before surgery and at 12 h post surgery. Vehicle-treated animals
received an equal volume of NS subcutaneously at the indicated
times. Mouse blood pressure was measured using the tail cuff
method as described previously.43 Mice were killed 24 h after surgery
and urine and blood were collected. Organs were collected for
further investigation.
Western immunoblot analyses
Cultured tubular epithelial cells were lysed and rat kidneys
homogenized in RIPA buffer supplemented with protease inhibitors.
Samples with equal amounts of total protein (50mg/ml) were
processed for immunoblot as described previously.22 The antibodies
against caspase-3, PARP, p-GSK3b, GSK3b, and actin were
purchased from Cell Signaling Technology (Beverly, MA), and
those against MCR were purchased from Alomone Labs.
Assessment of pulmonary edema
Lungs were removed from animals, placed in a tared microcen-
trifuge tube, and weighed. Lungs were then desiccated under
vacuum at 25 1C and weighed again. The wet lung mass was divided
by the dry lung mass to give the wet–dry ratio, which is the fraction
of the wet lung weight that was water.44
Measurement of blood and urine chemistry
Albumin levels in the ureteral urine were measured using a rat
Albumin ELISA Quantification kit (Bethyl Laboratories, Montgom-
ery, TX). Plasma corticosterone levels were measured by Corticoster-
one EIA Kits (Cayman Chemical, Ann Arbor, MI). Serum creatinine
levels were determined by a routine procedure as described
previously.25,45 To assess hepatotoxicity, serum activity of aspartate
aminotransferase and alanine aminotransferase were measured using
spectrophotometric ELISA kits (Uscn Life Science, Houston, TX).
Morphological studies
Formalin-fixed kidneys were embedded in paraffin and prepared in
3-mm-thick sections. Sections were stained with hematoxylin–eosin
to estimate gross histological kidney injury. One observer performed
computerized, as well as semiquantitative morphometric, analysis in
a blinded manner. Severity of tubulointerstitial injury and tubular
dilation/sloughing was semiquantitatively scored on a scale from 0
to 3 and reported as the mean of 20 random high-power (400)
fields per hematoxylin–eosin-stained section: 0, absent; 1, slight; 2,
moderate; 3, marked; 4, severe.22 Necroapoptotic nuclei were
defined as nuclei dropped off into the lumen or interstitium or
those with chromatin condensation, pyknosis, or fragmentation.
Indirect immunofluorescent staining of MCR was carried out on
methanol/acetone-fixed (1:1) frozen cryostat sections using anti-
MCR antibodies (Alomone Labs). Next, the Alexa Fluor
488–conjugated secondary antibodies (Invitrogen) were applied. As
a negative control, the primary antibodies were replaced by
preimmune IgG from the same species; no staining occurred.
Finally, all sections were mounted with Vectashield mounting
medium (Vector Laboratories). For visualization of fluorescence
RAM cells that were sequestrated in the organs, cryosections were
fixed with methanol/acetone and then subjected to Evans blue
counterstaining.
TUNEL staining
Apoptotic cell death in kidney sections was detected by using
the TUNEL kit (Roche Molecular Biochemicals, Mannheim,
Germany).25 Ten randomly selected 400 high-power fields
of juxtamedullary cortex were counted to determine the number
of apoptotic nuclei.
Statistical analyses
For immunoblot analysis, bands were scanned and the integrated
pixel density was determined using a densitometer and the NIH
image analysis program. All data are expressed as means±s.d.
Statistical analysis of the data from multiple groups was performed
by ANOVA followed by Student–Newman–Keuls tests. Data from
two groups were compared by t-test. Log-rank test was used for
Kaplan–Meier survival analysis. Po0.05 was considered significant.
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